Triple

T22717715
Position Surface form Disambiguated ID Type / Status
Subject Aubagio E561778 entity
Predicate hasGenericName P23148 FINISHED
Object teriflunomide — NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: teriflunomide | Statement: [Aubagio, hasGenericName, teriflunomide]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: teriflunomide
Context triple: [Aubagio, hasGenericName, teriflunomide]
  • A. Tecfidera
    Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
  • B. fingolimod
    Fingolimod is an oral disease-modifying immunomodulatory drug used to reduce relapses and delay disability progression in people with relapsing forms of multiple sclerosis.
  • C. Tysabri
    Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
  • D. methotrexate
    Methotrexate is a disease-modifying antirheumatic drug (DMARD) commonly used to treat autoimmune conditions such as rheumatoid arthritis, psoriasis, and certain cancers by inhibiting folate-dependent cell proliferation.
  • E. Remicade
    Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: teriflunomide
Target entity description: Teriflunomide is an immunomodulatory drug used primarily as an oral disease-modifying therapy for relapsing forms of multiple sclerosis.
  • A. Tecfidera
    Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
  • B. fingolimod
    Fingolimod is an oral disease-modifying immunomodulatory drug used to reduce relapses and delay disability progression in people with relapsing forms of multiple sclerosis.
  • C. Tysabri
    Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
  • D. methotrexate
    Methotrexate is a disease-modifying antirheumatic drug (DMARD) commonly used to treat autoimmune conditions such as rheumatoid arthritis, psoriasis, and certain cancers by inhibiting folate-dependent cell proliferation.
  • E. Remicade
    Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2454fc984819088213b58ee87a002 completed April 17, 2026, 2:35 p.m.
NER Named-entity recognition batch_69f1790ecbc48190926d16b20b674dbd completed April 29, 2026, 3:20 a.m.
Created at: April 17, 2026, 3:19 p.m.